Posts tagged Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency.
Blogs
less than a minute
On March 16, 2020, FDA finalized its guidance titled Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency (the “Policy”). The Policy includes information and recommendations to assist laboratories and commercial manufacturers in development of diagnostic tests for the novel coronavirus (“COVID-19”) during the ongoing pandemic.
During the first week of implementation, questions arose regarding the extent to which the Emergency Use Authorization (“EUA”) pathway to market, as described by the Policy, covers at-home ...
Blog Editors
Recent Updates
- Legislative Push for FDA Preemptive Authority Over Dietary Supplement Regulation
- GUARD and GLOBE Pricing Models Could Test Manufacturer Rebates for Medicare Part B and D Drugs
- FDA’s Office of Dietary Supplement Programs Signals Key Enforcement and Policy Priorities for the Year Ahead
- OIG Issues Guidance, Request for Information on DTC Programs
- OIG Greenlights Cost-Sharing Waiver for Commercially Insured Patients